期刊文献+

吉非替尼的合成 被引量:3

Synthesis of Gefitinib
原文传递
导出
摘要 3-羟基-4-甲氧基苯甲醛在甲酸和盐酸羟胺作用下转化为3-羟基-4-甲氧基苄腈,后者在碳酸钾存在下与N-(3-氯丙基)吗啉缩合得4-甲氧基-3-[3-(吗啉-4-基)]丙氧基苄腈,再经硝化制得2-硝基-4-甲氧基-5-[3-(吗啉-4-基)]丙氧基苄腈,经还原得2-氨基-4-甲氧基-5-[3-(吗啉-4-基)]丙氧基苄腈,后与3-氯-4-氟苯胺成脒得2-氨基-4-甲氧基-5-[3-(吗啉-4-基)]丙氧基-N'-(3-氯-4-氟苯基)苄脒,在甲酸作用下闭环得吉非替尼,总收率约44%。 Gefitinib was synthesized from 3-hydroxy-4-methoxybenzaldehyde via conversion ot aldehyde to nitrile, condensation with N-(3-chloropropyl)morpholine, nitration and reduction to give 2-amino-4-methoxy-5-(3- morpholin-4-ylpropoxy) benzonitrile, which was subjected to amidination with 3-chloro-4-fluoroaniline and cyclization in the presence of formic acid with an overall yield of about 44 %.
出处 《中国医药工业杂志》 CAS CSCD 北大核心 2013年第11期1081-1084,共4页 Chinese Journal of Pharmaceuticals
基金 江苏省"六大人才高峰"高层次人才项目(2011-JY-008) 连云港市工业攻关项目(CG1106)
关键词 吉非替尼 酪氨酸激酶抑制剂 Fe-Al-Cu复合催化剂 合成 gefitinib tyrosine kinase inhibitor Fe-A1-Cu complex catalyst synthesis
  • 相关文献

参考文献15

  • 1Fry DW, Kraker AJ, McMichael A, et ah A specific inhibitorof the epidermal growth factor receptor tyrosine kinase [J].Science, 1994,265(5175): 1093-1095. 被引量:1
  • 2Barker AJ, Gibson KH,Grundy W, et al. Studies leading tothe identification of ZD1839 (IRESSA): an orally active,selective epidermal growth factor receptor tyrosine kinaseinhibitor targeted to the treatment of cancer [J]. Bioorg MedChem Lett, 2001,11(14): 1911-1914. 被引量:1
  • 3张艳华,宁华,姜洋.表皮生长因子受体酪氨酸激酶抑制剂吉非替尼[J].中国新药杂志,2004,13(10):947-950. 被引量:13
  • 4Gibson KH. Preparation of haloanilinoquinazolines as ClassI receptor tyrosine kinase inhibitors: WO, 9633980 [P].1996-10-31. 被引量:1
  • 5朱崇泉,迟玉石,邓银来,等.4-(3-氯-4-氟苯基氨基)-7-甲氧基-6-(3-吗啉丙氧基)-4-喹唑啉:中国,1733738 [P].2006-02-15. 被引量:1
  • 6Gilday JP, Moody D. Process for the preparation of4- (3-chloro-4-fluoroanilino) -7-methoxy-6- (3-morpholino-propoxy)quinazoline: WO, 2004024703 [P]. 2004-03-25. 被引量:1
  • 7Wang JQ, Gao MZ, Miller KD, et al. Synthesis of [nC] Iressaas a new potential PET cancer imaging agent for epidermalgrowth factor receptor tyrosine kinase [J]. Bioorg Med ChemLett, 2006,16(15): 4102-4106. 被引量:1
  • 8刁圆圆,张庆文.吉非替尼的合成[J].中国医药工业杂志,2008,39(6):401-403. 被引量:14
  • 9Ramanadham JP, Muddasani PR, Bollepalli NR, et al. Animproved process for the preparation of gefitinib: WO,2005070909 [P]. 2005-08-04. 被引量:1
  • 10李美松,尚海萍.吉非替尼合成路线图解[J].中国医药工业杂志,2011,42(10):796-798. 被引量:6

二级参考文献48

  • 1张艳华,宁华,姜洋.表皮生长因子受体酪氨酸激酶抑制剂吉非替尼[J].中国新药杂志,2004,13(10):947-950. 被引量:13
  • 2[1]Natale R,Zaretsky SL.ZD1839 (IressaTM):what's in it for the patient[J].The Oncologist,2002,7(Suppl 4):S25-S30. 被引量:1
  • 3[2]Herbst RS,Kies MS.ZD1839 (IressaTM) in non-small-cell lung cancer[J].The Oncologist,2002,7(Suppl 4):S9-S15. 被引量:1
  • 4[3]Barker AJ,Gibson KH,Grundy W,et al.Studies leading to the identification of ZD1839(IRESSA):an orally active,selective epidermal growth factor receptor tyrosine kinase inhibitor targeted to the treatment of cancer[J].Bioorg Med Chem,2001,11(14):1911-1914. 被引量:1
  • 5[4]Iwasawa A,Kumamoto Y,Fujinaga K.Detection of human papillomavirus deoxyribonucleic acid in penile carcinoma by polymerase chain reaction and in situ hybridization[J].J Urol,1993,149(1):59-63. 被引量:1
  • 6[5]Varma VA,Sancher LMM,Unger ER,et al.Association of human papillomavirus with penile carcinoma:a study using polymerase chain reaction and in situ hybridization[J].Hum Pathol,1991,22(9):908-913. 被引量:1
  • 7[6]Gorgoulis V,Aninos D,Mikou P,et al.Quantitative assay of epidermal growth rceptor in squamous cell lung carcinomas[J].Anti Cancer Res,1992,12(4):1183. 被引量:1
  • 8[7]Swaisland H,Laight A,Stafford L,et al.Pharmacokinetics and tolerability of the orally active selective epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 in healthy volunteers[J].Clin Pharmacokinet,2001,40(4):297-306. 被引量:1
  • 9[8]Alderley P.ZD1839 ('Iressa'),an oral EGFR-TKI:pharmacokinetic results of a phase Ⅰstudy in patients with advanced cancer[A].AACR[C].San Francisco,CA,April 1-5,2000. 被引量:1
  • 10[9]Fukuoka M,Yano S,Giaccone G,et al.Final results from a Phase Ⅱ trial of ZD1839 ('Iressa') for patients with advanced non-small-cell lung cancer (IDEAL 1)[J].Proc Am Soc Clin Oncol,2002,21:298a(A1188). 被引量:1

共引文献83

同被引文献13

引证文献3

二级引证文献5

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部